Oncogene mutations in colorectal polyps identified in the Norwegian Colorectal Cancer Prevention (NORCCAP) screening study

Clinical Medicine Insights: Pathology

Volumn 9, Issue 1, 2016, Pages 19-28

  Lorentzen, Jon A ^a,b   Grzyb, Krzysztof ^a   De Angelis, Paula M ^a   Hoff, Geir ^b,c,d   Eide, Tor J ^a,b   Andresen, Per Arne ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c TELEMARK HOSPITAL   (Norway)

^d CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

Colonic polyps; Colorectal cancer screening; Oncogenes

Indexed keywords

B RAF KINASE; DNA;

ADULT; ARTICLE; BRAF GENE; CANCER RECURRENCE; CARCINOGENESIS; CODON; COLORECTAL CANCER; COLORECTAL POLYP; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KRAS GENE; MAJOR CLINICAL STUDY; MALE; NORWEGIAN (PEOPLE); ONCOGENE; PIK3CA GENE; SEX DIFFERENCE; TUBULOVILLOUS ADENOMA; TUMOR VOLUME;

EID: 84995527086     PISSN: 11795557     EISSN: None     Source Type: Journal    
DOI: 10.4137/CPath.s40143     Document Type: Article

References (53)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
2. Holme Ø, Løberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality. JAMA. 2014;312(6):606.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-67.
4. Yadamsuren E, Nagy S, Pajor L, Lacza A, Bogner B. Characteristics of advanced-and non advanced sporadic polypoid colorectal adenomas: correlation to KRAS mutations. Pathol Oncol Res. 2012;18(4):1077-84.
5. Maltzman T, Knoll K, Martinez ME, et al. Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology. 2001;121(2):302-9.
6. Ishii T, Notohara K, Umapathy A, et al. Tubular adenomas with minor villous changes show molecular features characteristic of tubulovillous adenomas. Am J Surg Pathol. 2011;35(2):212-20.
7. Sweetser S, Smyrk TC, Sinicrope FA. Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol. 2013;11(7):760-7.
8. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53(7):852-64.
9. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005;1756(2):81-2.
10. Govender D, Chetty R. Gene of the month: BRAF. J Clin Pathol. 2012; 65(11):986-8.
11. Lai K, Killingsworth MC, Lee CS. Gene of the month: PIK3CA. J Clin Pathol. 2015;68(4):253-7.
12. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II" study. Br J Cancer. 2001;85(5):692-6.
13. Tong JHM, Lung RWM, Sin FMC, et al. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther. 2014;15(6):768-76.
14. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753-62.
15. Imamura Y, Lochhead P, Yamauchi M, et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer. 2014;13(1):135.
16. Carr NJ, Mahajan H, Tan KL, Hawkins NJ, Ward RL. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol. 2009;62(6):516-8.
17. Sorbye H, Dragomir A, Sundström M, et al. High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLoS One. 2015;10(6):e0131046.
18. Kim M-J, Lee E-J, Suh J-P, et al. Traditional serrated adenoma of the colorectum: clinicopathologic implications and endoscopic findings of the precursor lesions. Am J Clin Pathol. 2013;140(6):898-911.
19. Whitehall VLJ, Rickman C, Bond CE, et al. Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer. 2012;131(4):813-20.
20. Eide TJ. Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer. 1986;38(2):173-6.
21. Morris RG, Curtis LJ, Romanowski P, et al. Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal mucosa. J Pathol. 1996;180(4): 357-63.
22. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian colorectal cancer prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol. 2003;38(6):635-42.
23. Church JM. Clinical significance of small colorectal polyps. Dis Colon Rectum. 2004;47(4):481-5.
24. Bretthauer M, Gondal G, Larsen IK, et al. Design, organization and management of a controlled population screening study for detection of colorectal neoplasia: attendance rates in the NORCCAP study (Norwegian colorectal cancer prevention). Scand J Gastroenterol. 2002;37(5):568-73.
25. Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC Press; 2010.
26. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014;43(D1):D805-11.
27. Ihle MA, Fassunke J, König K, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer. 2014;14(1):13.
28. Rashid A, Zahurak M, Goodman SN, Hamilton SR. Genetic epidemiology of mutated K-ras proto-oncogene, altered suppressor genes, and microsatellite instability in colorectal adenomas. Gut. 1999;44(6):826-33.
29. Kobayashi M, Watanabe H, Ajioka Y, Honma T, Asakura H. Effect of K-ras mutation on morphogenesis of colorectal adenomas and early cancers: relationship to distribution of proliferating cells. Hum Pathol. 1996;27(10):1042-9.
30. McLellan EA, Owen RA, Stepniewska KA, Sheffield JP, Lemoine NR. High frequency of K-ras mutations in sporadic colorectal adenomas. Gut. 1993;34(3):392-6.
31. Jass JR, Baker K, Zlobec I, et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a "fusion" pathway to colorectal cancer. Histopathology. 2006;49(2):121-31.
32. Cremolini C, Di Bartolomeo M, Amatu A, et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015;26(10):2092-7.
33. Ng SC, Ching JYL, Chan VCW, et al. Association between serrated polyps and the risk of synchronous advanced colorectal neoplasia in average-risk individuals. Aliment Pharmacol Ther. 2015;41(1):108-15.
34. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000;9(11):1193-7.
35. Al-Mulla F, Going JJ, Sowden ET, Winter A, Pickford IR, Birnie GD. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol. 1998;185(2):130-8.
36. Cespedes MV, Sancho FJ, Guerrero S, et al. K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis. 2006;27(11):2190-200.
37. Improta G, Zupa A, Possidente L, et al. Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: report of a case supporting the concept of tumoral heterogeneity. Oncol Lett. 2013;5(5):1741-3.
38. Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2012;9(12):e1001352.
39. Breivik J, Lothe RA, Meling GI, Rognum TO, Børresen-Dale AL, Gaudernack G. Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int J Cancer. 1997;74(6):664-9.
40. Lin Y-C, Chiu H-M, Lee Y-C, Shun C-T, Wang H-P, Wu M-S. Hyperplastic polyps identified during screening endoscopy: reevaluated by histological examinations and genetic alterations. J Formos Med Assoc. 2014;113(7):417-21.
41. Gerhardsson de Verdier M, London S. Reproductive factors, exogenous female hormones, and colorectal cancer by subsite. Cancer Causes Control. 1992;3(4): 355-60.
42. Chacko L, Macaron C, Burke CA. Colorectal cancer screening and prevention in women. Dig Dis Sci. 2015;60(3):698-710.
43. Chow L, Lin P-C, Chang JS, et al. Differences in the frequencies of K-ras c12-13 genotypes by gender and pathologic phenotypes in colorectal tumors measured using the allele discrimination method. Environ Mol Mutagen. 2012;53(1):22-31.
44. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 2003;24(4):703-10.
45. Rosty C, Young JP, Walsh MD, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol. 2013;26(6):825-34.
46. Jönsson M, Ekstrand A, Edekling T, et al. Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. BMC Clin Pathol. 2009;9(1):8.
47. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444(7119):638-42.
48. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011; 192(4):547-56.
49. Ohnishi T, Tomita N, Monden T, et al. A detailed analysis of the role of K-ras gene mutation in the progression of colorectal adenoma. Br J Cancer. 1997;75(3):341-7.
50. Jancík S, Drábek J, Radzioch D, Hajdúch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol. 2010;2010:150960.
51. Janakiraman M, Vakiani E, Zeng Z, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010;70(14): 5901-11.
52. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304(16):1812-20.
53. Denoyelle C, Abou-Rjaily G, Bezrookove V, et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol. 2006;8(10):1053-63.